Merck & Co., Inc.

NYSE:MRK

Drug Manufacturers - General

Healthcare
$137.78 -1.14%

-$1.32 today

Market cap
$339.66B
Beta
0.22
P/E (TTM)
31.6
EPS (TTM)
$3.61
Dividend yield
2.94%
52W Low $76.66High $125.14

Volume 9.69M

Average 11.85M

MRK Deferred Tax Liabilities

Taxes owed in future periods because of timing differences between accounting and tax rules.

Merck & Co., Inc.NYSE: MRK

Deferred Tax Liabilities · Q2 FY2026 · quarter ended Jun 2026

Deferred tax liabilities broadly unchanged from a year ago

Deferred tax liabilities stood at $1.43B at the end of Q2 FY2026, up 0.4% from a year earlier and down 4.1% from the prior quarter. Over 3 fiscal years it compounded at -7.1% a year.

Context

  • Deferred tax liabilities amounted to 1.1% of total assets at the end of Q2 FY2026, down 0.1 pp from a year earlier.
  • Deferred tax liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether deferred tax liabilities keeps rising in the next quarterly balance sheet after a +0.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.43B-4.1% QoQ
Last fiscal yearDec 2025
$1.44B+3.7% YoY
Year agoJun 2025
$1.43B+0.4% since
Deferred Tax Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.4%——
1 year+3.7%——
3-year CAGR-7.1%——
5-year CAGR——
10-year CAGR——

Deferred Tax Liabilities history

USD · from the balance sheet

Latest · FY2025
1.44B USD
Year-over-year change
+3.7%
4-year CAGR
-19.6%

Deferred Tax Liabilities vs competitors

How MRK compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred tax liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +0.4% is the 2nd highest of 9, against a peer median of -10.1%.
  • Deferred tax liabilities amounts to 1.1% of total assets for MRK, versus a peer median of 1.7%.
MRK Competitors
Deferred Tax Liabilities for MRK and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
LLYEli Lilly and CompanyJun 2026$5.46B USD——3.8%
NVSNovartis AGJun 2026$5.29B USD+128.0%+44.0%4.3%
JNJJohnson & JohnsonSep 2026$4.84B USD-19.3%+19.4%2.4%
AZNAstraZeneca PLCSep 2026$3.61B USD+0.2%+6.0%3.0%
ABBVAbbVie Inc.Jun 2026$2.28B USD-10.8%-2.9%1.7%
PFEPfizer Inc.Jun 2026$1.96B USD-20.8%+32.9%1.0%
SNYSanofiJun 2026€1.55B EUR-9.4%-3.3%1.2%
MRKMerck & Co., Inc.Jun 2026$1.43B USD+0.4%-7.1%1.1%
AMGNAmgen Inc.Jun 2026$1.3B USD-6.1%+398.9%1.4%
GILDGilead Sciences, Inc.Jun 2026$333M USD-48.9%-46.8%0.7%
Peer median (excluding MRK) —-10.1%+12.7%1.7%

Competitors are the stored peer set for MRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents8.1B12.69B6.84B13.24B14.57B
Short-term Investments0498M252M447M0
Net Receivables9.23B9.45B10.35B10.28B12.68B
Inventory5.95B5.91B6.36B6.11B6.66B
Other Current Assets6.99B7.17B8.37B8.71B9.49B
Total Current Assets30.27B35.72B32.17B38.78B43.52B
Property, Plant & Equipment (Net)19.28B21.42B23.05B23.78B26.82B
Goodwill21.26B21.2B21.2B21.67B21.58B
Intangible Assets22.93B20.27B18.01B16.37B26.68B
Long-term Investments370M1.02B252M463M2.24B
Tax Assets00000
Other Non-current Assets11.58B9.53B12B16.04B16.03B
Total Non-current Assets75.43B73.44B74.51B78.32B93.35B
Total Assets105.69B109.16B106.68B117.11B136.87B
Account Payables4.61B4.26B3.92B4.08B4.4B
Short-term Debt2.41B1.95B1.37B2.65B2.88B
Tax Payables1.22B1.99B2.65B3.91B0
Deferred Revenue00000
Other Current Liabilities(304M)(281M)(285M)(282M)14.09B
Total Current Liabilities23.87B24.24B25.69B28.42B28.33B
Long-term Debt30.69B28.75B33.68B34.46B46.75B
Deferred Tax Liabilities3.44B1.8B871M1.39B1.44B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities8.21B7.31B7.86B5.59B6.79B
Total Non-current Liabilities43.57B38.86B43.35B42.31B55.88B
Total Liabilities67.44B63.1B69.04B70.73B84.2B
Common Stock1.79B1.79B1.79B1.79B1.79B
Retained Earnings53.7B61.08B53.9B63.07B73.08B
Accumulated OCI(4.43B)(4.77B)(5.16B)(4.95B)(4.29B)
Other Stockholders Equity00000
Minority Interest73M67M54M59M56M
Total Equity38.26B46.06B37.64B46.37B52.66B
Total Debt34.63B31.99B36.27B38.27B50.53B
Net Debt26.54B19.29B29.43B25.03B35.97B

Merck & Co., Inc.

NYSE:MRK

Intrinsic Alpha fair value

Locked

Current Price

$137.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.